Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2025

Nov 14, 2025

SELL
$1.36 - $2.18 $33,864 - $54,282
-24,900 Reduced 10.7%
207,800 $453,000
Q2 2025

Aug 14, 2025

BUY
$1.06 - $1.63 $246,662 - $379,301
232,700 New
232,700 $295,000

Others Institutions Holding ERAS

About Erasca, Inc.


  • Ticker ERAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 122,147,000
  • Market Cap $315M
  • Description
  • Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...
More about ERAS
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.